Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 [ABT 335] and Statin Therapy [HMG-CoA reductase inhibitors] for Subjects With Mixed Dyslipidemia.

Next Previous
Trial Profile

A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 [ABT 335] and Statin Therapy [HMG-CoA reductase inhibitors] for Subjects With Mixed Dyslipidemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Choline fenofibrate (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
  • Indications Dyslipidaemias
  • Focus Adverse reactions; Registrational
  • Sponsors Abbott Laboratories

Most Recent Events

  • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 12 Jun 2008 Patient numbers amended from 300 to 310 as reported by ClinicalTrials.gov
  • 12 Jun 2008 The expected completion date for this trial is Nov 2008 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top